{"id":"standard-of-care-oral-antipsychotics","safety":{"commonSideEffects":[{"rate":"5-30","effect":"Extrapyramidal symptoms (tremor, rigidity, akathisia)"},{"rate":"10-40","effect":"Weight gain"},{"rate":"10-30","effect":"Metabolic syndrome (hyperglycemia, dyslipidemia)"},{"rate":"10-50","effect":"Sedation"},{"rate":"20-50","effect":"Prolactin elevation"},{"rate":"5-20","effect":"Orthostatic hypotension"},{"rate":"1-5","effect":"QT prolongation"}]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oral antipsychotics work primarily through antagonism of dopamine D2 receptors, which reduces hyperactivity in dopaminergic pathways associated with psychosis. Many also have serotonin 5-HT2A receptor antagonism, which contributes to antipsychotic and mood-stabilizing effects. The class includes both first-generation (typical) agents that are primarily dopamine antagonists and second-generation (atypical) agents with broader receptor profiles.","oneSentence":"Standard of care oral antipsychotics block dopamine and/or serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:09:23.949Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar disorder"},{"name":"Psychotic disorders"},{"name":"Acute agitation in psychiatric patients"}]},"trialDetails":[{"nctId":"NCT06245213","phase":"PHASE2","title":"A Study of ANAVEX3-71 in Adults With Schizophrenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anavex Life Sciences Corp.","startDate":"2024-03-15","conditions":"Schizophrenia","enrollment":71},{"nctId":"NCT04940039","phase":"PHASE4","title":"A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2021-07-22","conditions":"Schizophrenia","enrollment":93},{"nctId":"NCT02237417","phase":"PHASE4","title":"Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-09-01","conditions":"Schizophrenia","enrollment":47},{"nctId":"NCT05402111","phase":"PHASE1","title":"A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-06-13","conditions":"Schizophrenia","enrollment":31},{"nctId":"NCT05542264","phase":"PHASE1","title":"A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-11-15","conditions":"Schizophrenia","enrollment":19},{"nctId":"NCT05762146","phase":"PHASE2","title":"Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE","status":"UNKNOWN","sponsor":"Maastricht University","startDate":"2022-09-05","conditions":"Ischemic Stroke, Acute","enrollment":28},{"nctId":"NCT00845026","phase":"PHASE2","title":"A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2009-03","conditions":"Schizophrenia","enrollment":261},{"nctId":"NCT01052103","phase":"PHASE2","title":"A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2010-01","conditions":"Schizophrenia","enrollment":167},{"nctId":"NCT03892889","phase":"PHASE3","title":"A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2019-04-29","conditions":"Schizophrenia","enrollment":277},{"nctId":"NCT03319953","phase":"PHASE2","title":"A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2017-12-21","conditions":"Stable Schizophrenia","enrollment":23},{"nctId":"NCT00712270","phase":"PHASE4","title":"Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia","status":"TERMINATED","sponsor":"Kettering Health Network","startDate":"2005-04","conditions":"Schizophrenia","enrollment":21},{"nctId":"NCT01567124","phase":"PHASE4","title":"Alleviating the Metabolic Side Effects of Antipsychotic Medications","status":"WITHDRAWN","sponsor":"Baker Heart and Diabetes Institute","startDate":"2012-05","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT02928965","phase":"PHASE2","title":"The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms","status":"COMPLETED","sponsor":"University of Manchester","startDate":"2013-02","conditions":"Schizophrenia and Disorders With Psychotic Features","enrollment":207},{"nctId":"NCT00693472","phase":"PHASE2","title":"Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-08-15","conditions":"Akathisia, Drug-Induced, Antipsychotic Agents, Movement Disorders","enrollment":46},{"nctId":"NCT01192867","phase":"PHASE3","title":"A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-12-11","conditions":"Schizophrenia","enrollment":629},{"nctId":"NCT02079844","phase":"PHASE1","title":"Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-03","conditions":"Schizophrenia","enrollment":20},{"nctId":"NCT02282085","phase":"PHASE4","title":"Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia","status":"UNKNOWN","sponsor":"Matt Byerly","startDate":"2014-12","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT01129674","phase":"PHASE2, PHASE3","title":"A Long-Term, Open-Label, Study on Schizophrenia","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2010-06","conditions":"Schizophrenia","enrollment":1210},{"nctId":"NCT01420575","phase":"NA","title":"Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia","status":"TERMINATED","sponsor":"VA Nebraska Western Iowa Health Care System","startDate":"2010-10","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":8},{"nctId":"NCT00086112","phase":"PHASE3","title":"Study Comparing Risperidone vs Placebo as add-on Therapy in Patients With Generalized Anxiety Disorder Who Are Sub-optimally Responding to Standard Therapy.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"","conditions":"Anxiety Disorders","enrollment":301},{"nctId":"NCT00249171","phase":"PHASE4","title":"A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2001-06","conditions":"Schizophrenia, Psychotic Disorders, Emergency Treatment","enrollment":226}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Standard of Care Oral antipsychotics","genericName":"Standard of Care Oral antipsychotics","companyName":"University of Utah","companyId":"university-of-utah","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Standard of care oral antipsychotics block dopamine and/or serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar disorder, Psychotic disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}